JP2011525370A - ヒト多能性幹細胞からヒト代用皮膚を調製するための方法 - Google Patents
ヒト多能性幹細胞からヒト代用皮膚を調製するための方法 Download PDFInfo
- Publication number
- JP2011525370A JP2011525370A JP2011515354A JP2011515354A JP2011525370A JP 2011525370 A JP2011525370 A JP 2011525370A JP 2011515354 A JP2011515354 A JP 2011515354A JP 2011515354 A JP2011515354 A JP 2011515354A JP 2011525370 A JP2011525370 A JP 2011525370A
- Authority
- JP
- Japan
- Prior art keywords
- human
- stem cells
- cells
- pluripotent stem
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 56
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 55
- 210000004027 cell Anatomy 0.000 claims abstract description 162
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 127
- 210000003491 skin Anatomy 0.000 claims abstract description 79
- 230000004069 differentiation Effects 0.000 claims abstract description 37
- 230000006698 induction Effects 0.000 claims abstract description 14
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 230000011712 cell development Effects 0.000 claims abstract description 8
- 230000008093 supporting effect Effects 0.000 claims abstract description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 41
- 210000002950 fibroblast Anatomy 0.000 claims description 34
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 32
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 21
- 229960005070 ascorbic acid Drugs 0.000 claims description 20
- 235000010323 ascorbic acid Nutrition 0.000 claims description 20
- 239000011668 ascorbic acid Substances 0.000 claims description 20
- 230000002500 effect on skin Effects 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 238000004113 cell culture Methods 0.000 claims description 14
- 230000037380 skin damage Effects 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 239000012598 cell culture matrix Substances 0.000 claims description 2
- 231100000676 disease causative agent Toxicity 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 abstract description 9
- 239000010410 layer Substances 0.000 description 36
- 230000014509 gene expression Effects 0.000 description 27
- 238000010171 animal model Methods 0.000 description 24
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 23
- 210000002615 epidermis Anatomy 0.000 description 23
- 239000002609 medium Substances 0.000 description 21
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 20
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 229960004857 mitomycin Drugs 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- 102000011782 Keratins Human genes 0.000 description 11
- 108010076876 Keratins Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 9
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
- 101710183391 Keratin, type I cytoskeletal 14 Proteins 0.000 description 8
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 8
- 108010066321 Keratin-14 Proteins 0.000 description 8
- 108010070553 Keratin-5 Proteins 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 7
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000003981 ectoderm Anatomy 0.000 description 7
- 108010028309 kalinin Proteins 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 5
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 5
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 5
- 108010066327 Keratin-18 Proteins 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- 102000009016 Cholera Toxin Human genes 0.000 description 4
- 108010049048 Cholera Toxin Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229930192392 Mitomycin Natural products 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 102100028314 Filaggrin Human genes 0.000 description 3
- 101710088660 Filaggrin Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 3
- 108010065038 Keratin-10 Proteins 0.000 description 3
- 108010070511 Keratin-8 Proteins 0.000 description 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
- 102100027881 Tumor protein 63 Human genes 0.000 description 3
- 229940088623 biologically active substance Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 102000007236 involucrin Human genes 0.000 description 3
- 108010033564 involucrin Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000007431 microscopic evaluation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940035722 triiodothyronine Drugs 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- 101710087047 Cytoskeleton-associated protein 4 Proteins 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001015006 Homo sapiens Integrin beta-4 Proteins 0.000 description 2
- 101000976051 Homo sapiens Involucrin Proteins 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 102100033000 Integrin beta-4 Human genes 0.000 description 2
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 2
- 108010070514 Keratin-1 Proteins 0.000 description 2
- 108010066302 Keratin-19 Proteins 0.000 description 2
- 208000034607 Kindler epidermolysis bullosa Diseases 0.000 description 2
- 201000004290 Kindler syndrome Diseases 0.000 description 2
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 2
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 2
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- 101700032040 SMAD1 Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 101710140697 Tumor protein 63 Proteins 0.000 description 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000002169 ectodermal dysplasia Diseases 0.000 description 2
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000002514 epidermal stem cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010090250 Growth Differentiation Factor 6 Proteins 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100024629 Laminin subunit beta-3 Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
- 102100030607 Mothers against decapentaplegic homolog 9 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 102000005601 Receptor-Regulated Smad Proteins Human genes 0.000 description 1
- 108010084447 Receptor-Regulated Smad Proteins Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101700026522 SMAD7 Proteins 0.000 description 1
- 101700031501 SMAD9 Proteins 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 108010075526 keratohyalin Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000108 skin corrosion Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/395—Thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08305320 | 2008-06-25 | ||
| EP08305320.7 | 2008-06-25 | ||
| EP08305447.8 | 2008-08-04 | ||
| EP08305447 | 2008-08-04 | ||
| US9095708P | 2008-08-22 | 2008-08-22 | |
| US61/090,957 | 2008-08-22 | ||
| EP09305077 | 2009-01-28 | ||
| EP09305077.1 | 2009-01-28 | ||
| PCT/EP2009/057817 WO2009156398A1 (en) | 2008-06-25 | 2009-06-23 | Methods for preparing human skin substitutes from human pluripotent stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011525370A true JP2011525370A (ja) | 2011-09-22 |
| JP2011525370A5 JP2011525370A5 (enExample) | 2012-08-09 |
Family
ID=40863382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515354A Pending JP2011525370A (ja) | 2008-06-25 | 2009-06-23 | ヒト多能性幹細胞からヒト代用皮膚を調製するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110165130A1 (enExample) |
| EP (1) | EP2297299A1 (enExample) |
| JP (1) | JP2011525370A (enExample) |
| KR (1) | KR20110022713A (enExample) |
| CN (1) | CN102186969A (enExample) |
| AU (1) | AU2009264336A1 (enExample) |
| BR (1) | BRPI0914422A2 (enExample) |
| WO (1) | WO2009156398A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015125941A1 (ja) * | 2014-02-21 | 2015-08-27 | 株式会社ヘリオス | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
| JP2016513469A (ja) * | 2013-03-15 | 2016-05-16 | ザ ジャクソン ラボラトリー | 非胚性幹細胞の単離とその使用 |
| JP2016135102A (ja) * | 2014-12-22 | 2016-07-28 | ザ チャイニーズ ユニバーシティ オブ ホンコン | 体細胞から多能性幹細胞を作製するための機械的操作とプログラミンの併用 |
| US10676720B2 (en) | 2014-12-22 | 2020-06-09 | The Chinese University Of Hong Kong | Combinational use of mechanical manipulation and programin derivatives to increase Oct4, Sox2, Nanog or c-Myc expression in fibroblasts |
| JP2023018632A (ja) * | 2022-02-16 | 2023-02-08 | 株式会社コーセー | 多能性幹細胞から表皮角化細胞への分化誘導方法 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2010134619A1 (ja) * | 2009-05-18 | 2012-11-12 | 国立大学法人東北大学 | 人工多能性幹細胞からの上皮系前駆細胞・幹細胞群及び角膜上皮細胞群の分化誘導方法 |
| US8529883B2 (en) | 2010-05-07 | 2013-09-10 | Fibrocell Technologies, Inc. | Dosage unit formulations of autologous dermal fibroblasts |
| RU2458983C1 (ru) * | 2011-07-18 | 2012-08-20 | Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации | Способ получения индуцированных плюрипотентных стволовых клеток из фибробластов пациентов с болезнью хангингтона |
| US20160237400A1 (en) * | 2013-03-15 | 2016-08-18 | The Jackson Laboratory | Isolation of non-embryonic stem cells and uses thereof |
| US9545302B2 (en) | 2013-11-20 | 2017-01-17 | Dermagenesis Llc | Skin printing and auto-grafting |
| CN104789521B (zh) * | 2014-01-22 | 2017-11-07 | 广州康睿生物医药科技股份有限公司 | 一种晶状体上皮干细胞的分离培养方法 |
| US20180230436A1 (en) * | 2014-10-10 | 2018-08-16 | Garrett VYGANTAS | Methods of manufacturing keratin products and uses thereof |
| GB201510913D0 (en) * | 2015-06-22 | 2015-08-05 | Nat University Of Singapore And Agency For Science Technology And Res | Vascularized tissue, skin or mucosa quivalent |
| SG11201803061UA (en) | 2015-10-21 | 2018-05-30 | Univ Indiana Res & Tech Corp | Methods of generating human inner ear sensory epithelia and sensory neurons |
| WO2017070506A1 (en) * | 2015-10-21 | 2017-04-27 | Indiana University Research And Technology Corporation | Derivation of human skin organoids from pluripotent stem cells |
| US10273549B2 (en) * | 2016-04-21 | 2019-04-30 | Vitrolabs Inc. | Engineered skin equivalent, method of manufacture thereof and products derived therefrom |
| EP4074818A3 (en) * | 2016-12-09 | 2023-01-18 | The University of Chicago | Tissue organoids |
| CN106754652B (zh) * | 2017-03-06 | 2019-04-02 | 广州润虹医药科技股份有限公司 | iPS细胞分化成外胚层祖细胞的无血清诱导培养基及诱导方法 |
| CN106834214B (zh) * | 2017-03-27 | 2020-02-14 | 广州润虹医药科技股份有限公司 | 一种诱导多能干细胞形成角质形成细胞的诱导培养基及诱导方法 |
| CN110914406A (zh) * | 2017-06-30 | 2020-03-24 | 思特科技公司 | 从尿液细胞直接逆分化为角质形成细胞干细胞的方法及利用逆分化的角质形成细胞干细胞的用于促进皮肤再生的组合物的制备方法 |
| CN107988147B (zh) * | 2017-12-19 | 2021-11-09 | 江汉大学 | 基于器官芯片与诱导多能干细胞的定向分化用于3d拟表皮构建的方法 |
| CN110093306B (zh) * | 2018-01-31 | 2022-12-02 | 中山大学 | 人工毛囊及其制备方法和应用 |
| EP3875580A1 (en) | 2020-03-02 | 2021-09-08 | Centre d'Etude des Cellules Souches (CECS) | Methods for preparing keratinocytes |
| EP3875124A1 (fr) | 2020-03-02 | 2021-09-08 | Urgo Recherche Innovation Et Developpement | Procede d'obtention d'un tissu dermo-epidermique pre-vascularise |
| EP3875581A1 (en) * | 2020-03-02 | 2021-09-08 | Centre d'Etude des Cellules Souches (CECS) | Automated method for preparing keratinocytes |
| CN113046300B (zh) * | 2021-03-19 | 2024-08-06 | 上海爱萨尔生物科技有限公司 | 一种基于多能干细胞分化制备角质细胞的培养方法 |
| CN112941015B (zh) * | 2021-03-19 | 2022-03-18 | 上海爱萨尔生物科技有限公司 | 一种基于多能干细胞分化制备角质细胞的添加剂及方法 |
| CN112980775B (zh) * | 2021-03-19 | 2024-01-23 | 上海爱萨尔生物科技有限公司 | 一种基于多能干细胞分化制备角质细胞的培养液 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2825370A1 (fr) * | 2001-05-31 | 2002-12-06 | Inst Nat Sante Rech Med | Keratinocytes obtenus a partir de cellules souches embryonnaires de mammiferes |
-
2009
- 2009-06-23 EP EP09769247A patent/EP2297299A1/en not_active Withdrawn
- 2009-06-23 US US12/999,129 patent/US20110165130A1/en not_active Abandoned
- 2009-06-23 WO PCT/EP2009/057817 patent/WO2009156398A1/en not_active Ceased
- 2009-06-23 JP JP2011515354A patent/JP2011525370A/ja active Pending
- 2009-06-23 CN CN2009801256559A patent/CN102186969A/zh active Pending
- 2009-06-23 AU AU2009264336A patent/AU2009264336A1/en not_active Abandoned
- 2009-06-23 KR KR1020117001947A patent/KR20110022713A/ko not_active Withdrawn
- 2009-06-23 BR BRPI0914422A patent/BRPI0914422A2/pt not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| JPN5011006198; ＡＢＥＲＤＡＭ ＥＤＩＴＨ: 'Ａ ＰＵＲＥ ＰＯＰＵＬＡＴＩＯＮ ＯＦ ＥＣＴＯＤＥＲＭＡＬ ＣＥＬＬＳ ＤＥＲＩＶＥＤ ＦＲＯＭ ＨＵＭＡＮ ＥＭＢＲＹＯＮＩＣ ＳＴＥＭ ＣＥＬＬＳ' ＳＴＥＭ ＣＥＬＬＳ Ｖ２６ Ｎ２, 200802, Ｐ４４０-４４４ * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016513469A (ja) * | 2013-03-15 | 2016-05-16 | ザ ジャクソン ラボラトリー | 非胚性幹細胞の単離とその使用 |
| JP2020055796A (ja) * | 2014-02-21 | 2020-04-09 | 大日本住友製薬株式会社 | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
| KR20160116008A (ko) * | 2014-02-21 | 2016-10-06 | 가부시키가이샤 헤리오스 | 눈 질환 치료제, 이의 스크리닝 방법, 및 망막 색소 상피 세포 이식과 연관된 거부 반응의 예측 방법 |
| JPWO2015125941A1 (ja) * | 2014-02-21 | 2017-03-30 | 株式会社ヘリオス | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
| US10240201B2 (en) | 2014-02-21 | 2019-03-26 | Healios K.K. | Eye disease treatment agent, screening method therefor, and method for predicting rejection response associated with retinal pigment epithelial cell transplant |
| WO2015125941A1 (ja) * | 2014-02-21 | 2015-08-27 | 株式会社ヘリオス | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
| KR102354410B1 (ko) | 2014-02-21 | 2022-01-21 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 눈 질환 치료제, 이의 스크리닝 방법, 및 망막 색소 상피 세포 이식과 연관된 거부 반응의 예측 방법 |
| JP2016135102A (ja) * | 2014-12-22 | 2016-07-28 | ザ チャイニーズ ユニバーシティ オブ ホンコン | 体細胞から多能性幹細胞を作製するための機械的操作とプログラミンの併用 |
| US10676720B2 (en) | 2014-12-22 | 2020-06-09 | The Chinese University Of Hong Kong | Combinational use of mechanical manipulation and programin derivatives to increase Oct4, Sox2, Nanog or c-Myc expression in fibroblasts |
| JP2023018632A (ja) * | 2022-02-16 | 2023-02-08 | 株式会社コーセー | 多能性幹細胞から表皮角化細胞への分化誘導方法 |
| JP7315184B2 (ja) | 2022-02-16 | 2023-07-26 | 株式会社コーセー | 多能性幹細胞から表皮角化細胞への分化誘導方法 |
| WO2023157852A1 (ja) * | 2022-02-16 | 2023-08-24 | 株式会社コーセー | 多能性幹細胞から表皮角化細胞への分化誘導方法 |
| KR20240144127A (ko) | 2022-02-16 | 2024-10-02 | 가부시키가이샤 코세 | 다능성 줄기세포로부터 표피각질형성세포로의 분화 유도 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009156398A1 (en) | 2009-12-30 |
| KR20110022713A (ko) | 2011-03-07 |
| CN102186969A (zh) | 2011-09-14 |
| BRPI0914422A2 (pt) | 2017-03-21 |
| EP2297299A1 (en) | 2011-03-23 |
| AU2009264336A1 (en) | 2009-12-30 |
| US20110165130A1 (en) | 2011-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525370A (ja) | ヒト多能性幹細胞からヒト代用皮膚を調製するための方法 | |
| JP2011525370A5 (enExample) | ||
| JP4950661B2 (ja) | 分娩後由来細胞類を使用する、神経組織の再生および修復 | |
| JP6821908B2 (ja) | 哺乳動物種における誘導組織再生のための組成物および方法 | |
| JP5017253B2 (ja) | 羊膜由来細胞組成物、その作製方法および使用 | |
| EP2447357B1 (en) | Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations | |
| RU2612391C2 (ru) | Лечение амиотрофического бокового склероза с использованием полученных из пуповины клеток | |
| US20190367883A1 (en) | Regulating stem cells | |
| KR20070001108A (ko) | 각막 윤부로부터 유도된 미분화 줄기 세포를 가진 조직시스템 | |
| CN101330935A (zh) | 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用 | |
| KR20120120971A (ko) | 인간 다능성 줄기 세포로부터 인간 멜라닌세포를 제조하는 방법 | |
| JP2016516394A (ja) | ヒト線維芽細胞において特徴的な幹細胞であるＭｕｓｅ細胞から容易に分化した機能性メラノサイトの使用 | |
| Dong et al. | Enrichment of epidermal stem cells by rapid adherence and analysis of the reciprocal interaction of epidermal stem cells with neighboring cells using an organotypic system | |
| Schatten | Cell and molecular biology and imaging of stem cells | |
| Zhou et al. | A novel experimental study on establish a myoblasts differentiated cell sheet using induced adipose-derived stem cell technology | |
| JP2005287478A (ja) | ヒト脂肪前駆細胞株及びその利用方法 | |
| Shamis | hESC-and iPSC-Derived Fibroblasts for Skin Engineering and Repair | |
| IL193947A (en) | Cells cultured as cd31brigi: it, a method for stimuli to differentiate into a congenital / precursor cell population (pcp), use of the same drug preparation population, and implantation device that includes it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120619 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140408 |